Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 16Thoracic 12Gynecologic 11Genitourinary 11Other solid neoplasm 9Head & Neck 7Breast 5Dermatologic 3Endocrine 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1NET 1Lymphoid 1CNS 1

Conditions

Recurrence 1Glioblastoma 1

Interventions

Temozolomide 623Radiotherapy 410Bevacizumab 256Magnetic Resonance Spectroscopy 226Cyclophosphamide 179Radiosurgery 162Carboplatin 160Etoposide 132Radiation 128Vincristine 115Irinotecan 115Cisplatin 103Filgrastim 100Specimen Handling 90Nivolumab 88pembrolizumab 83Surgical Procedures, Operative 83Lomustine 82Topotecan 73Doxorubicin 61Melphalan 59Carmustine 57Radiotherapy, Intensity-Modulated 56sargramostim 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 51Chemotherapy, Adjuvant 51Blood Specimen Collection 51Erlotinib Hydrochloride 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
zimberelimab × CNS × Clear all
NCT04656535 2026-04-17

AB154 Combined With AB122 for Recurrent Glioblastoma

Yale University

Phase EARLY_PHASE1 Active not recruiting
46 enrolled
CNS

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡